Carmot Therapeutics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2008-01-01
- Employees
- 57
- Market Cap
- -
- Website
- http://carmot.us
A Study of CT-388 in Participants Who Are Overweight or Obese with Type 2 Diabetes Mellitus
- Conditions
- Overweight or ObeseType 2 Diabetes Mellitus (T2DM)
- Interventions
- Drug: CT-388Drug: Placebo
- First Posted Date
- 2024-10-08
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Carmot Therapeutics, Inc.
- Target Recruit Count
- 360
- Registration Number
- NCT06628362
- Locations
- 🇺🇸
Accellacare of Piedmont Healthcare, Statesville, North Carolina, United States
🇺🇸Accellacare of Wilmington, LLC, Wilmington, North Carolina, United States
🇺🇸Accellacare Research of Winston Salem, Winston Salem, North Carolina, United States
A Study of CT-388 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity
- Conditions
- ObesityOverweight
- Interventions
- Drug: PlaceboDrug: CT-388
- First Posted Date
- 2024-07-29
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Carmot Therapeutics, Inc.
- Target Recruit Count
- 450
- Registration Number
- NCT06525935
- Locations
- 🇺🇸
Alabama Clinical Therapeutics, LLC, Birmingham, Alabama, United States
🇺🇸Central Alabama Research, Homewood, Alabama, United States
🇺🇸The Institute for Liver Health II LLC dba Arizona Clinical Trials; Arizona Liver Health, Mesa, Arizona, United States
A Study of CT-868 in Type 1 Diabetes Mellitus
- Conditions
- ObeseType 1 Diabetes MellitusOverweight
- Interventions
- Drug: CT-868Device: CT-868 Pen Injector
- First Posted Date
- 2023-10-02
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- Carmot Therapeutics, Inc.
- Target Recruit Count
- 96
- Registration Number
- NCT06062069
- Locations
- 🇺🇸
Carmot Therapeutics Investigational Site 108, Shavano Park, Texas, United States
🇺🇸Carmot Therapeutics Investigational Site 109, Renton, Washington, United States
🇺🇸Carmot Therapeutics Investigational Site 103, Dallas, Texas, United States
A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes
- First Posted Date
- 2023-04-03
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Carmot Therapeutics, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT05794581
- Locations
- 🇺🇸
Carmot Clinical Research Unit 101, Chula Vista, California, United States
A Study of CT-868 in Overweight and Obese Participants With Type 2 Diabetes Mellitus
- Conditions
- ObesityType2 Diabetes
- Interventions
- Drug: PlaceboDrug: CT-868
- First Posted Date
- 2021-11-08
- Last Posted Date
- 2022-07-26
- Lead Sponsor
- Carmot Therapeutics, Inc.
- Target Recruit Count
- 96
- Registration Number
- NCT05110846
- Locations
- 🇲🇽
Carmot Clinical Center MX05, Mérida, Yucatan, Mexico
🇲🇽Carmot Clinical Center MX03, Mexico City, Mexico
🇲🇽Carmot Clinical Center MX04, Guadalajara, Jalisco, Mexico
A Study to Assess CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood Glucose.
- Conditions
- Diabetes
- Interventions
- Drug: CT-868 as SC InjectionDrug: Placebo as SC InjectionDrug: Active Comparator as SC Injection
- First Posted Date
- 2021-07-22
- Last Posted Date
- 2022-05-03
- Lead Sponsor
- Carmot Therapeutics, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT04973111
- Locations
- 🇺🇸
Carmot Clinical Research Unit 101, Chula Vista, California, United States
A Study of CT-388 in Otherwise Healthy Overweight and Obese Adults and Patients With Type 2 Diabetes Mellitus
- Conditions
- Diabetes
- Interventions
- Drug: CT-388Drug: Placebo
- First Posted Date
- 2021-04-09
- Last Posted Date
- 2022-07-26
- Lead Sponsor
- Carmot Therapeutics, Inc.
- Target Recruit Count
- 96
- Registration Number
- NCT04838405
- Locations
- 🇦🇺
Carmot Clinical Research Unit 101, Perth, Western Australia, Australia
🇲🇽Carmot Clinical Research Unit 105, Monterrey, Nuevo Leon, Mexico